Agilent Technologies Inc (A), a leader in life sciences, diagnostics, and applied chemical markets, is set to release its Q4 earnings report on November 25. Wall Street anticipates earnings of $1.41 per share, marking a 2.2% year-over-year increase, while quarterly revenues are projected at $1.67 billion, reflecting a slight decline of 0.9% compared to the same period last year.
Is now the time to buy Agilent? Access our full analysis report here, it’s free.
Expected Q4 Earnings Report of Agilent Technologies Inc:
- Consensus estimates for Agilent Technologies have remained stable over the past 30 days, with no revisions to earnings per share (EPS).
- Analysts project revenue growth in the following key sectors:
- Diagnostics and Clinical: +3.2%
- Chemical and Advanced Materials: +1.2%
- Diagnostics and Genomics: +17.3%
- Revenue declines are anticipated in other sectors:
- Academia and Government: -7.8%
- Environmental and Forensics: -4.6%
- Life Sciences and Applied Markets Group: -11.7%
- The Agilent CrossLab Group is expected to report a net revenue increase of 6.8%, showcasing resilience in this segment.
Stock Target Advisor’s Analysis on Agilent Technologies Inc:
According to Stock Target Advisor, Agilent Technologies maintains a “Slightly Bullish” outlook based on 11 positive signals and 5 negative indicators. Strengths include superior risk-adjusted returns, positive cash flow, and high gross profit-to-asset ratio. However, challenges include overpricing relative to book and cash flow values, as well as below-median revenue and earnings growth over the past five years.
Currently priced at $128.57, the stock has experienced a -10.26% change over the past month but remains up by 3.69% year-over-year. The average analyst target price stands at $143.59, with a projected 12-month price increase of 12.54%.
Conclusion:
Agilent Technologies Inc faces a mixed outlook as it approaches its Q4 earnings announcement. While growth in Diagnostics and Genomics and strong performance in the Agilent CrossLab Group are positive signs, declines in other segments and challenges in valuation metrics could weigh on investor sentiment. The coming report will be crucial in shaping the stock’s trajectory in the near term.
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
